Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Oncolytics Biotech
(NASDAQ:ONCY)
Intraday
$1.08
0
[0.00%]
After-Hours
$1.08
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.08
0
[0.00%]
At close: Apr 26
$1.08
0
[0.00%]
After Hours: 8:34AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Oncolytics Biotech Stock (NASDAQ:ONCY)
Oncolytics Biotech Stock (NASDAQ: ONCY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
Oncolytics Reports Acceptance Of Two Abstracts At The 2024 American Society Of Clinical Oncology Annual Meeting
Benzinga Newsdesk
-
1 day ago
Thursday, April 11, 2024
Oncolytics Biotech Has Submitted Type C Meeting Request To FDA For Q2 2024 To Discuss The Company's Planned Registration-enabling Trial For Pelareorep In HR+/HER2- Metastatic Breast Cancer
Benzinga Newsdesk
-
Apr 11, 2024, 7:20AM
Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA
Benzinga Newsdesk
-
Apr 11, 2024, 7:05AM
Thursday, April 04, 2024
Raymond James Initiates Coverage On Oncolytics Biotech with Outperform Rating, Announces Price Target of $3
Benzinga Newsdesk
-
Apr 4, 2024, 1:47PM
Friday, March 08, 2024
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk
-
Mar 8, 2024, 1:04PM
Thursday, March 07, 2024
Recap: Oncolytics Biotech Q4 Earnings
Benzinga Insights
-
Mar 7, 2024, 4:10PM
Oncolytics Biotech Q4 EPS $(0.04) Beats $(0.11) Estimate
Benzinga Newsdesk
-
Mar 7, 2024, 4:07PM
Earnings Scheduled For March 7, 2024
Benzinga Insights
-
Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
A Preview Of Oncolytics Biotech's Earnings
Benzinga Insights
-
Mar 6, 2024, 2:02PM
Tuesday, March 05, 2024
Oncolytics Biotech Submits Amendment To GOBLET To Initiate New Phase 1/2 Cohort Evaluating Pelareorep In Combination With Modified FOLFIRINOX With And Without Tecentriq
Benzinga Newsdesk
-
Mar 5, 2024, 7:10AM
Wednesday, February 14, 2024
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk
-
Feb 14, 2024, 1:45PM
Friday, January 19, 2024
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk
-
Jan 19, 2024, 7:02AM
Thursday, January 04, 2024
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk
-
Jan 4, 2024, 10:26AM
Oncolytics Biotech Says It Expects To Initiate First Phase 3 Study For Pelareorep In Pancreatic Cancer This Year, Company Will Provide Guidance On Registration Path For Metastatic Breast Cancer In First Half Of 2024
Benzinga Newsdesk
-
Jan 4, 2024, 7:08AM
Thursday, December 07, 2023
Oncolytics Biotech Presented Additional Translational Data From the AWARE-1 Breast Cancer Window-Of-Opportunity Study Done In Combination With SOLTI-Innovative Cancer Research
Benzinga Newsdesk
-
Dec 7, 2023, 7:04AM
Monday, November 13, 2023
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
Benzinga Newsdesk
-
Nov 13, 2023, 11:16AM
Thursday, November 09, 2023
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep, Updated Plan Follows PanCAN's Re-Evaluation Of Precision Promise Program
Benzinga Newsdesk
-
Nov 9, 2023, 6:35AM
Friday, November 03, 2023
Earnings Scheduled For November 3, 2023
Benzinga Insights
-
Nov 3, 2023, 7:12AM
Oncolytics Biotech Q3 EPS Loss Widens To $(0.10)
Benzinga Newsdesk
-
Nov 3, 2023, 7:04AM
Thursday, November 02, 2023
Oncolytics Biotech's Earnings Outlook
Benzinga Insights
-
Nov 2, 2023, 3:01PM
Monday, October 23, 2023
Oncolytics Biotech Achieves Success Criteria For Efficacy In The Third-Line Colorectal Cancer Cohort Of The Phase 1/2 GOBLET Study
Benzinga Newsdesk
-
Oct 23, 2023, 7:07AM
Tuesday, September 26, 2023
The Pancreatic Cancer Action Network Selects Oncolytics Biotech Inc. To Receive $5M Therapeutic Accelerator Award To Develop Leading-Edge Treatments
Benzinga Newsdesk
-
Sep 26, 2023, 8:01AM
Oncolytics Biotech Bags $5M Therapeutic Accelerator Award From The Pancreatic Action Network
Benzinga Newsdesk
-
Sep 26, 2023, 7:04AM
Wednesday, August 16, 2023
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
Benzinga Newsdesk
-
Aug 16, 2023, 10:29AM
Tuesday, August 15, 2023
RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
Benzinga Newsdesk
-
Aug 15, 2023, 11:03AM
Monday, August 14, 2023
CORRECTION: Oncolytics Biotech Q2 EPS $(0.09), Inline; Cash, Cash Equivalents Of $24.4M
Benzinga Newsdesk
-
Aug 14, 2023, 7:14AM
Oncolytics Biotech Q2 EPS $(0.09), Inline; Cash, Cash Equivalents Of $24.4M
Benzinga Newsdesk
-
Aug 14, 2023, 7:05AM
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
Friday, August 11, 2023
Oncolytics Biotech's Earnings: A Preview
Benzinga Insights
-
Aug 11, 2023, 11:01AM
Tuesday, August 08, 2023
Oncolytics Biotech Successfully Raises $15M To Advance Breast And Pancreatic Cancer Clinical Programs
Happy Mohamed
-
Aug 8, 2023, 9:01AM
Monday, July 31, 2023
Oncolytis Biotech shares are trading lower after the company announced that it entered into an agreement with Leede Jones Gable as an underwriter and bookrunner to purchase, on a brought-deal basis, 6.667 million units for gross proceeds of $15 million at $2.25 per unit.
Benzinga Newsdesk
-
Jul 31, 2023, 12:27PM
Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit
Benzinga Newsdesk
-
Jul 31, 2023, 6:58AM
Thursday, June 29, 2023
5 Analysts Have This to Say About Oncolytics Biotech
Benzinga Insights
-
Jun 29, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
Benzinga Newsdesk
-
Jun 29, 2023, 11:52AM
Friday, June 23, 2023
Canaccord Genuity Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk
-
Jun 23, 2023, 10:41AM
Thursday, June 22, 2023
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jun 22, 2023, 1:09PM
Wednesday, June 14, 2023
Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research
Benzinga Newsdesk
-
Jun 14, 2023, 9:13AM
Wednesday, June 07, 2023
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
Benzinga Newsdesk
-
Jun 7, 2023, 6:54AM
Monday, June 05, 2023
Oncolytics Biotech Reports Updated Randomized Phase 2 Data From BRACELET-1 Metastatic Breast Cancer Trial
Benzinga Newsdesk
-
Jun 5, 2023, 7:06AM
Friday, May 26, 2023
Expert Ratings for Oncolytics Biotech
Benzinga Insights
-
May 26, 2023, 5:01PM
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
May 26, 2023, 12:48PM
Thursday, May 25, 2023
Oncolytics Biotech Reports Randomized Phase 2 Data From BRACELET-1 Metastatic Breast Cancer Trial In ASCO Annual Meeting Abstract
Benzinga Newsdesk
-
May 25, 2023, 5:45PM
Wednesday, May 24, 2023
Oncolytics Biotech shares are trading higher after JonesTrading initiated covered on the stock with a Buy rating and announced a $9 price target.
Benzinga Newsdesk
-
May 24, 2023, 12:40PM
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Benzinga Insights
-
May 24, 2023, 11:00AM
JonesTrading Initiates Coverage On Oncolytics Biotech with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk
-
May 24, 2023, 4:46AM
Monday, May 08, 2023
RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
Benzinga Newsdesk
-
May 8, 2023, 9:06AM
Friday, May 05, 2023
Oncolytics Biotech: Q1 Earnings Insights
Benzinga Insights
-
May 5, 2023, 7:15AM
Oncolytics Biotech Says Cash Balance Of C$29.7M Is Expected To Provide Projected Cash Runway For At Least 12 Months
Benzinga Newsdesk
-
May 5, 2023, 7:14AM
Oncolytics Biotech Q1 EPS $(0.07) Beats $(0.10) Estimate
Benzinga Newsdesk
-
May 5, 2023, 7:11AM
Earnings Scheduled For May 5, 2023
Benzinga Insights
-
May 5, 2023, 5:59AM
Show more